Zacks Research Has Optimistic Outlook of PAHC Q2 Earnings

Phibro Animal Health Corporation (NASDAQ:PAHC) – Analysts at Zacks Research upped their Q2 2026 earnings per share (EPS) estimates for shares of Phibro Animal Health in a note issued to investors on Wednesday, September 10th. Zacks Research analyst Team now anticipates that the company will earn $0.71 per share for the quarter, up from their previous estimate of $0.60. Zacks Research has a “Hold” rating on the stock. The consensus estimate for Phibro Animal Health’s current full-year earnings is $1.95 per share. Zacks Research also issued estimates for Phibro Animal Health’s Q3 2026 earnings at $0.66 EPS, Q1 2027 earnings at $0.58 EPS, Q2 2027 earnings at $0.69 EPS, Q3 2027 earnings at $0.62 EPS, Q4 2027 earnings at $0.59 EPS, FY2027 earnings at $2.49 EPS and FY2028 earnings at $2.92 EPS.

Phibro Animal Health (NASDAQ:PAHC) last issued its earnings results on Wednesday, August 27th. The company reported $0.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.52 by $0.05. Phibro Animal Health had a return on equity of 32.14% and a net margin of 3.73%.The business had revenue of $378.70 million during the quarter, compared to the consensus estimate of $362.24 million. Phibro Animal Health has set its FY 2026 guidance at 2.520-2.700 EPS.

Other equities analysts have also recently issued reports about the company. BNP Paribas Exane upgraded Phibro Animal Health from an “underperform” rating to a “neutral” rating and set a $24.00 price target for the company in a report on Monday, June 16th. Morgan Stanley set a $34.00 price target on Phibro Animal Health in a report on Thursday, August 28th. BNP Paribas upgraded Phibro Animal Health to a “hold” rating in a report on Monday, June 16th. JPMorgan Chase & Co. upgraded Phibro Animal Health from a “neutral” rating to an “overweight” rating and increased their price target for the stock from $25.00 to $35.00 in a report on Monday, July 7th. Finally, Bank of America increased their price target on Phibro Animal Health from $19.00 to $27.00 and gave the stock an “underperform” rating in a report on Friday, August 29th. One investment analyst has rated the stock with a Buy rating, four have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Phibro Animal Health presently has an average rating of “Reduce” and a consensus target price of $28.40.

Phibro Animal Health Stock Up 0.0%

Shares of PAHC opened at $41.19 on Thursday. Phibro Animal Health has a 52-week low of $16.16 and a 52-week high of $41.57. The company has a market capitalization of $1.67 billion, a PE ratio of 34.91, a price-to-earnings-growth ratio of 1.23 and a beta of 0.89. The stock has a fifty day simple moving average of $31.75 and a two-hundred day simple moving average of $25.38. The company has a quick ratio of 1.25, a current ratio of 2.76 and a debt-to-equity ratio of 2.46.

Hedge Funds Weigh In On Phibro Animal Health

Several hedge funds have recently bought and sold shares of PAHC. Price T Rowe Associates Inc. MD boosted its stake in shares of Phibro Animal Health by 9.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 17,668 shares of the company’s stock valued at $372,000 after buying an additional 1,565 shares during the period. Northern Trust Corp boosted its stake in shares of Phibro Animal Health by 7.2% in the 4th quarter. Northern Trust Corp now owns 245,110 shares of the company’s stock valued at $5,147,000 after buying an additional 16,421 shares during the period. Ameriprise Financial Inc. boosted its stake in shares of Phibro Animal Health by 31.2% in the 4th quarter. Ameriprise Financial Inc. now owns 90,782 shares of the company’s stock valued at $1,906,000 after buying an additional 21,576 shares during the period. Cetera Investment Advisers purchased a new position in shares of Phibro Animal Health in the 4th quarter valued at about $204,000. Finally, Cubist Systematic Strategies LLC purchased a new position in shares of Phibro Animal Health in the 4th quarter valued at about $1,119,000. Institutional investors and hedge funds own 99.34% of the company’s stock.

Insider Transactions at Phibro Animal Health

In related news, CEO Jack Bendheim sold 14,080 shares of the stock in a transaction dated Tuesday, September 9th. The stock was sold at an average price of $40.33, for a total transaction of $567,846.40. Following the transaction, the chief executive officer owned 45,400 shares of the company’s stock, valued at approximately $1,830,982. This represents a 23.67% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 50.07% of the company’s stock.

Phibro Animal Health Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 24th. Investors of record on Wednesday, September 3rd will be paid a dividend of $0.12 per share. The ex-dividend date of this dividend is Wednesday, September 3rd. This represents a $0.48 annualized dividend and a yield of 1.2%. Phibro Animal Health’s dividend payout ratio is presently 40.68%.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.